Webinars and Sponsored Roundtables — Register Now
Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Product Spotlight
Altera Digital Health
| Company | Altera Digital Health |
|---|---|
| Name of laboratory information system | Altera Lab |
| Contact | Jennifer Sutton |
| City, State | Niagara Falls, NY |
| Phone | 800-334-8534 |
| Website | |
| Company provides list of client sites to potential customers on request | yes (partial list of comparable sites but prospective clients must sign a nondisclosure agreement) |
| Updates covered by standard software maintenance fee | all updates |
| Schedule for providing standard software updates to clients | annually or as needed |
| Clients must install updates in specified timespans to avoid maintenance fee increase | yes |
| Fee for software modifications to comply with federal regulations and laws | no |
| Year company began selling LISs (any brand or model) | 1999 |
| Most recent LIS go-live at a client site (based on August 2025 survey deadline) | Apr-2025 |
| Last product release or update for featured LIS | 23 |
| No. of U.S. sales and installations of LIS between August 2024–July 2025 | 2 sales/1 installation |
| Total No. of U.S. sites operating LIS (hospitals/independent labs/clinics or group practices/public health labs/other sites) | 31 (31/0/0/0/0) |
| • Approx. percentage of high-vol.* U.S. site installs/Low-vol.** U.S. site installs | 50%/50% |
| Foreign locations where company actively markets LIS for clinical lab use | none |
| • Foreign locations where LIS has been installed for clinical lab use | — |
| Human languages (other than English) supported by LIS | — |
| Approximate No. of employees in entire company | 5, 500 |
| Central hardware or service type | HP, IBM, Dell, Azure |
| Programming languages and development applications or environments | C, C#, Java, JavaScript, Perl, HTML |
| Operating system(s) | Microsoft Windows, Red Hat Enterprise Linux, Oracle Linux |
| Databases | Oracle |
| System includes full transaction logging | yes |
| • Chemistry/Hematology/Print barcoded collection labels | installed at client sites (all 3 features) |
| • Microbiology/Public health microbiology | installed at client sites/installed at client sites |
| • Blood bank donor/Blood bank transfusion | not available/available via WellSky, Haemonetics |
| • Surgical pathology/Cytology | available via NovoPath/available via NovoPath |
| • Molecular pathology/Cytogenetics/Flow cytometry | available via NovoPath/available via NovoPath/available via NovoPath |
| • EHR interface for admission/discharge/transfer (ADT) | installed at client sites |
| • EHR interface for order entry/EHR interface for results reporting | installed at client sites/installed at client sites |
| • EHR interface+GQ3:GQ15 for packaging results into PDF format | installed at client sites |
| • EHR interface for packaging results into CDA1 format/CDA2 format | not available/not available |
| • Ad hoc reporting/Rules-based system | installed at client sites/installed at client sites |
| • Management and statistical reporting/Client services or CRM module | installed at client sites/not available |
| • POL link or Web portal to physician offices/Patient Web portal | not available/not available |
| • Commercial reference lab functionality/Compliance checking | installed at client sites/not available |
| • Comprehensive billing and accounts receivable or RCM | not available |
| • Materials management and inventory/Test partition | not available/not available |
| • Remote faxing/Remote printing | installed at client sites/installed at client sites |
| • HIPAA-standard transaction formats | installed at client sites |
| • Web-based remote inquiry of reports/Web access for order entry | not available/not available |
| • Management and tracking of specimens within lab/Before arriving in lab | installed at client sites/installed at client sites |
| • QA tools/Environmental health | installed at client sites/installed at client sites |
| • Interfaces for sending orders from primary lab to reference lab, handling results return, and status updates | installed at client sites |
| • Business analytics/Clinical analytics | installed at client sites/installed at client sites |
| • Ability to schedule patient for test collection/Patient-based test registration | not available/installed at client sites |
| • Ability to coordinate with nurses for collections that phlebotomists cannot perform | installed at client sites |
| • Interfaces with public health databases using ELR as part of Promoting Interoperability | installed at client sites |
| • Results for tests run using different methods show method on clinical reports | installed at client sites |
| Barcode symbologies supported by LIS | Code 39, Code 128 |
| Ability to use artificial intelligence (e.g., machine-learning software) with LIS | planned for future |
| • Microbiology (culture and sensitivity) | yes |
| • Other reportable diseases or conditions (e.g., blood lead, immunology, etc.) | yes |
| • Tumor diagnosis and case data to regional cancer registry*** | no |
| LIS bidirectionally interfaces to other IT vendors’ lab systems in live sites | yes |
| LIS uses third-party middleware for LIS–instrument interfaces | yes (Data Innovations) |
| Lab automation systems or workcells to which LIS has a direct interface | interface via Data Innovations to Beckman Coulter, Siemens, QuidelOrtho, Sysmex, Roche, Abbott |
| LIS supports use of SNOMED CT | yes, for all cases |
| LIS automatically ingests and applies electronic updates of tables and rules from organizations and government agencies | planned for future |
| LIS allows for image capture, display, reporting | yes |
| LIS provides indexed field in each test definition for LOINC code | yes (provide LOINC dictionary free of charge with install) |
| Client gets copy of source code/User group that meets on established schedule | escrow/yes (via conference call) |
| Qualified users or third parties can modify or augment LIS functions or features | yes (client users and designated third parties) |
| Methods by which users can tailor LIS in their own setting | ad hoc query tools, user-defined interfaces, dictionary settings, read/write privileges, workflow configuration, tailored worklists, interface engine |
| Distinguishing product features (supplied by company) | expert microbiology: uses decision tree logic to perform systematic phrase and microbiology result entry; expert technology: supports laboratory policies and practices, confirming that analytical criteria are applied; label designer: allows users to easily create custom labels with text, barcodes, and shapes |
| Notes | — |